NephroPlus Expands Global Footprint in Dialysis Services
NephroPlus sharpens global dialysis push as overseas business grows

Image: Business Standard
NephroPlus, based in Hyderabad, India, is transforming into a global dialysis network, with international revenue surging from 12% to 42% in three years. The company plans to open 40-50 clinics annually in India and 15-16 in the Philippines, aiming for a 15-20% annual revenue growth over the next few years.
- 01NephroPlus operates over 520 clinics across India, the Philippines, Saudi Arabia, Uzbekistan, and Nepal.
- 02The company's revenue for FY26 reached ₹998.8 crore (approximately $120 million USD), a 32.2% increase from the previous year.
- 03Dialysis pricing in the Philippines is significantly higher than in India, with treatments costing around $110 compared to $22–25 in India.
- 04NephroPlus's blended revenue per treatment rose to ₹2,598 (approximately $31 USD) in FY26, boosted by favorable exchange rates and reimbursement increases.
- 05The company estimates that India needs an additional 65,000 dialysis machines and 5,000 centers to meet growing demand.
Advertisement
In-Article Ad
NephroPlus, the only publicly listed dialysis company in Asia, is shifting its focus from India to become a global dialysis network. Currently the fifth-largest dialysis provider worldwide, the company operates over 520 clinics across multiple countries including India, the Philippines, Saudi Arabia, Uzbekistan, and Nepal. Its international revenue surged from 12% in FY23 to nearly 42% in FY26, driven by acquisitions and partnerships. NephroPlus aims to open 40–50 clinics annually in India and 15–16 clinics in the Philippines, with plans for further international expansion. In FY26, the company reported a revenue of ₹998.8 crore (approximately $120 million USD), a 32.2% increase year-on-year, while treatment volumes rose 16.6% to 3.84 million sessions. The pricing for dialysis treatments is notably higher in international markets, with the Philippines charging around $110 per session compared to $22–25 in India, enhancing profitability. Despite aggressive overseas expansion, NephroPlus continues to prioritize India, where demand for dialysis is growing due to an estimated 220,000 new end-stage renal disease patients annually.
Advertisement
In-Article Ad
NephroPlus's expansion will improve access to dialysis treatment in underserved regions, particularly in tier-2 and tier-3 cities in India.
Advertisement
In-Article Ad
Reader Poll
Should NephroPlus prioritize international expansion over domestic growth?
Connecting to poll...
Read the original article
Visit the source for the complete story.



